BR112017023232A2 - pcr em tempo real da amplificação da ligação imperfeita diversificada otimizada (moma) para a avaliação do dna livre de células - Google Patents

pcr em tempo real da amplificação da ligação imperfeita diversificada otimizada (moma) para a avaliação do dna livre de células

Info

Publication number
BR112017023232A2
BR112017023232A2 BR112017023232A BR112017023232A BR112017023232A2 BR 112017023232 A2 BR112017023232 A2 BR 112017023232A2 BR 112017023232 A BR112017023232 A BR 112017023232A BR 112017023232 A BR112017023232 A BR 112017023232A BR 112017023232 A2 BR112017023232 A2 BR 112017023232A2
Authority
BR
Brazil
Prior art keywords
moma
diversified
optimized
real
time pcr
Prior art date
Application number
BR112017023232A
Other languages
English (en)
Portuguese (pt)
Inventor
Tomita Mitchell Aoy
Stamm Karl
Mitchell Michael
Original Assignee
Medical College Of Wisconsin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College Of Wisconsin Inc filed Critical Medical College Of Wisconsin Inc
Publication of BR112017023232A2 publication Critical patent/BR112017023232A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112017023232A 2015-04-30 2016-04-29 pcr em tempo real da amplificação da ligação imperfeita diversificada otimizada (moma) para a avaliação do dna livre de células BR112017023232A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562155453P 2015-04-30 2015-04-30
PCT/US2016/030313 WO2016176662A1 (en) 2015-04-30 2016-04-29 Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cell-free dna

Publications (1)

Publication Number Publication Date
BR112017023232A2 true BR112017023232A2 (pt) 2018-08-07

Family

ID=56027193

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017023232A BR112017023232A2 (pt) 2015-04-30 2016-04-29 pcr em tempo real da amplificação da ligação imperfeita diversificada otimizada (moma) para a avaliação do dna livre de células

Country Status (12)

Country Link
US (1) US20180142296A1 (cg-RX-API-DMAC7.html)
EP (1) EP3289102A1 (cg-RX-API-DMAC7.html)
JP (2) JP2018514219A (cg-RX-API-DMAC7.html)
CN (1) CN107849604A (cg-RX-API-DMAC7.html)
AU (2) AU2016255573A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017023232A2 (cg-RX-API-DMAC7.html)
CA (1) CA2984352A1 (cg-RX-API-DMAC7.html)
EA (1) EA201792389A1 (cg-RX-API-DMAC7.html)
HK (1) HK1252152A1 (cg-RX-API-DMAC7.html)
IL (2) IL255301B (cg-RX-API-DMAC7.html)
MX (1) MX2017013878A (cg-RX-API-DMAC7.html)
WO (1) WO2016176662A1 (cg-RX-API-DMAC7.html)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11773434B2 (en) 2017-06-20 2023-10-03 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free DNA
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11946101B2 (en) 2015-05-11 2024-04-02 Natera, Inc. Methods and compositions for determining ploidy
US12020778B2 (en) 2010-05-18 2024-06-25 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12100478B2 (en) 2012-08-17 2024-09-24 Natera, Inc. Method for non-invasive prenatal testing using parental mosaicism data
US12110552B2 (en) 2010-05-18 2024-10-08 Natera, Inc. Methods for simultaneous amplification of target loci
US12146195B2 (en) 2016-04-15 2024-11-19 Natera, Inc. Methods for lung cancer detection
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
US12260934B2 (en) 2014-06-05 2025-03-25 Natera, Inc. Systems and methods for detection of aneuploidy
US12270073B2 (en) 2010-05-18 2025-04-08 Natera, Inc. Methods for preparing a biological sample obtained from an individual for use in a genetic testing assay
US12305229B2 (en) 2014-04-21 2025-05-20 Natera, Inc. Methods for simultaneous amplification of target loci
US12410476B2 (en) 2010-05-18 2025-09-09 Natera, Inc. Methods for simultaneous amplification of target loci
US12460264B2 (en) 2016-11-02 2025-11-04 Natera, Inc. Method of detecting tumour recurrence
US12509728B2 (en) 2005-07-29 2025-12-30 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US12571043B2 (en) 2005-11-26 2026-03-10 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US12655483B2 (en) 2010-05-18 2026-06-16 Natera, Inc. Methods for simultaneous amplification of target loci

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
EP2854058A3 (en) 2010-05-18 2015-10-28 Natera, Inc. Methods for non-invasive pre-natal ploidy calling
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
AU2011348100B2 (en) 2010-12-22 2016-08-25 Natera, Inc. Methods for non-invasive prenatal paternity testing
US10385396B2 (en) 2012-04-19 2019-08-20 The Medical College Of Wisconsin, Inc. Highly sensitive surveillance using detection of cell free DNA
PL3117012T5 (pl) 2014-03-14 2026-03-16 Caredx, Inc. Sposoby monitorowania terapii immunosupresyjnych u biorcy przeszczepu
RU2717641C2 (ru) 2014-04-21 2020-03-24 Натера, Инк. Обнаружение мутаций и плоидности в хромосомных сегментах
AU2016255573A1 (en) * 2015-04-30 2017-12-21 The Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (MOMA)-real time PCR for assessing cell-free DNA
CA3022572A1 (en) 2016-04-29 2017-11-02 The Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-target number
EA201892491A1 (ru) * 2016-04-29 2019-06-28 Дзе Медикал Колледж Оф Висконсин, Инк. Пцр в реальном времени с мультиплексной оптимизированной амплификацией неправильно спаренных оснований (moma) для анализа злокачественных новообразований
BR112018072197A2 (pt) * 2016-04-29 2019-02-12 Medical College Wisconsin Inc amplificação de emparelhamento optimizado múltiplo (moma) - pcr de tempo real para avaliar o poço fetal
WO2018067517A1 (en) 2016-10-04 2018-04-12 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
US20190367972A1 (en) * 2016-11-02 2019-12-05 The Medical College Of Wisconsin, Inc. Methods for assessing risk using total and specific cell-free dna
AU2017355458A1 (en) * 2016-11-02 2019-06-13 The Medical College Of Wisconsin, Inc. Methods for assessing risk using mismatch amplification and statistical methods
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
CN111094593A (zh) * 2017-06-20 2020-05-01 威斯康星州立大学医学院 使用供体特异性无细胞dna来评估移植对象中的病症
US20210139983A1 (en) * 2017-06-20 2021-05-13 The Medical College Of Wisconsin, Inc. Transplant patient monitoring with cell-free dna
AU2018317875A1 (en) * 2017-08-17 2020-03-05 Tai Diagnostics, Inc. Methods of determining donor cell-free DNA without donor genotype
SG11202005474RA (en) * 2017-12-15 2020-07-29 Acrannolife Genomics Pvt Ltd A non-invasive method for monitoring transplanted organ status in organ-transplant recipients
EP3737773B1 (en) 2018-01-12 2023-04-12 Natera, Inc. Novel primers and uses thereof
EP3847280A1 (en) 2018-09-07 2021-07-14 Sequenom, Inc. Methods, and systems to detect transplant rejection
EP3899033A4 (en) * 2018-12-17 2022-10-19 The Medical College of Wisconsin, Inc. Assessing risk with total cell-free dna
WO2020206290A1 (en) * 2019-04-03 2020-10-08 The Medical College Of Wisconsin, Inc. Methods for assessing risk using total cell-free dna
US12305235B2 (en) 2019-06-06 2025-05-20 Natera, Inc. Methods for detecting immune cell DNA and monitoring immune system
WO2021236962A1 (en) 2020-05-20 2021-11-25 The Medical College Of Wisconsin, Inc. Compositions and methods for inhibiting cytokine-release syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60123448T2 (de) * 2001-12-24 2007-08-23 Prof. Wolfgang Holzgreve Verfahren zur nicht-invasiven Diagnose von Transplantationen und Transfusionen
DK2496720T3 (da) * 2009-11-06 2020-09-28 Univ Leland Stanford Junior Ikke-invasiv diagnose af transplantatafstødning i organ-transplanterede patienter
US20130143219A1 (en) * 2010-01-28 2013-06-06 Medical College of Wisconsin Inc. Methods and compositions for high yield, specific amplification
CN102892901B (zh) * 2010-03-24 2015-11-25 凸版印刷株式会社 利用竞争性引物的目标碱基序列的检测方法
US10385396B2 (en) * 2012-04-19 2019-08-20 The Medical College Of Wisconsin, Inc. Highly sensitive surveillance using detection of cell free DNA
HK1217971A1 (zh) * 2013-02-21 2017-01-27 Toma Biosciences Inc 用於核酸分析的方法、組合物和試劑盒
PL3004388T5 (pl) * 2013-05-29 2023-10-09 Chronix Biomedical Wykrywanie i oznaczanie ilościowe pozakomórkowego dna dawcy w układzie krążenia biorców przeszczepów organów
AU2016255573A1 (en) * 2015-04-30 2017-12-21 The Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (MOMA)-real time PCR for assessing cell-free DNA

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12509728B2 (en) 2005-07-29 2025-12-30 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US12571043B2 (en) 2005-11-26 2026-03-10 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US12110552B2 (en) 2010-05-18 2024-10-08 Natera, Inc. Methods for simultaneous amplification of target loci
US12649946B2 (en) 2010-05-18 2026-06-09 Natera, Inc. Methods for simultaneous amplification of target loci
US12020778B2 (en) 2010-05-18 2024-06-25 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12655483B2 (en) 2010-05-18 2026-06-16 Natera, Inc. Methods for simultaneous amplification of target loci
US12410476B2 (en) 2010-05-18 2025-09-09 Natera, Inc. Methods for simultaneous amplification of target loci
US12662704B2 (en) 2010-05-18 2026-06-23 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US12270073B2 (en) 2010-05-18 2025-04-08 Natera, Inc. Methods for preparing a biological sample obtained from an individual for use in a genetic testing assay
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US12100478B2 (en) 2012-08-17 2024-09-24 Natera, Inc. Method for non-invasive prenatal testing using parental mosaicism data
US12305229B2 (en) 2014-04-21 2025-05-20 Natera, Inc. Methods for simultaneous amplification of target loci
US12260934B2 (en) 2014-06-05 2025-03-25 Natera, Inc. Systems and methods for detection of aneuploidy
US11946101B2 (en) 2015-05-11 2024-04-02 Natera, Inc. Methods and compositions for determining ploidy
US12146195B2 (en) 2016-04-15 2024-11-19 Natera, Inc. Methods for lung cancer detection
US12460264B2 (en) 2016-11-02 2025-11-04 Natera, Inc. Method of detecting tumour recurrence
US11773434B2 (en) 2017-06-20 2023-10-03 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free DNA
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12385096B2 (en) 2018-04-14 2025-08-12 Natera, Inc. Methods for cancer detection and monitoring
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples

Also Published As

Publication number Publication date
JP2018514219A (ja) 2018-06-07
AU2016255573A1 (en) 2017-12-21
IL289404A (en) 2022-02-01
JP2022002508A (ja) 2022-01-11
MX2017013878A (es) 2018-06-22
EP3289102A1 (en) 2018-03-07
US20180142296A1 (en) 2018-05-24
CA2984352A1 (en) 2016-11-03
AU2022203482A1 (en) 2022-06-09
IL255301B (en) 2022-02-01
EA201792389A1 (ru) 2018-05-31
CN107849604A (zh) 2018-03-27
WO2016176662A1 (en) 2016-11-03
IL255301A0 (en) 2017-12-31
HK1252152A1 (zh) 2019-05-17

Similar Documents

Publication Publication Date Title
BR112018072196A2 (pt) amplificação de incompatibilidade otimizada multiplexadas (moma) - número do alvo
EA201792389A1 (ru) Пцр в реальном времени для мультиплексной оптимизированной амплификации с несоответствиями (moma) и для оценки неклеточной днк
BR112018072195A2 (pt) amplificação de incompatibilidade otimizada multiplexado (moma) - pcr de tempo real para avaliar o câncer
MX2019005199A (es) Métodos para evaluar el riesgo usando and libre de células total y específico.
BR112018072197A2 (pt) amplificação de emparelhamento optimizado múltiplo (moma) - pcr de tempo real para avaliar o poço fetal
BR112017024747A2 (pt) composições e métodos para enriquecer populações de ácidos nucleicos
PT3882357T (pt) Métodos e composições para análise de ácidos nucleicos
WO2015195949A3 (en) Methods, compositions, and devices for rapid analysis of biological markers
FI3901281T3 (fi) Biologisten näytteiden spatiaalisesti eroteltu moninkertainen nukleiinihappoanalyysi
DK3583214T3 (da) Fremgangsmåder og sammensætninger til identificering eller kvantificering af mål i en biologisk prøve
EP3571230A4 (en) COMPOSITIONS AND METHODS FOR DELETION OF CD137 + CELLS
GB201200658D0 (en) Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence
DK3325669T3 (da) Sammensætninger og fremgangsmåder til RNA-analyse
UA115321C2 (uk) Спосіб та комплект для аналізу ahasl генів у рослин
MX2016016898A (es) Metodos y composiciones para analisis de muestras.
EP3129035C0 (en) COMPOSITIONS AND METHODS FOR INDUCING TH17 CELLS
DK4026917T3 (da) Fremgangsmåde og kit til bestemmelse af cellers eller vævs død eller dna's vævs- eller celleoprindelse ved dna-methyleringsanalyse
BR112017017025A2 (pt) métodos e composições para analizar componentes celulares
DK3471733T3 (da) Reagenser, sammensætninger og fremgangsmåder til forbedring af cellers, vævs og organers levedygtighed og funktion
MX386087B (es) Composiciones y metodos para mejorar y/o predecir la amplificacion de adn.
MX2018009505A (es) Metodo para determinar helicobacter pylori.
GB2576836B (en) Compositions and methods for multiplexed quantitative analysis of cell lineages
ZA202101476B (en) Methods and compositions for nucleic acid isolation
BR112017005200A2 (pt) composição, formulação comestível, e, método para aumentar o ferro sérico em um mamífero com necessidade do mesmo.
GB201800184D0 (en) Compositions and methods for delivery of nucleic acid plant cells

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: THE MEDICAL COLLEGE OF WISCONSIN, INC. (US)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2668 DE 22-02-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.